scholarly journals Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Mina Abedi ◽  
Sepideh Alavi-Moghadam ◽  
Moloud Payab ◽  
Parisa Goodarzi ◽  
Fereshteh Mohamadi-jahani ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Systemic Sclerosis ◽  
Mesenchymal Stem Cell ◽  
Epidemiological Data ◽  
Current Status ◽  
Future Perspectives ◽  
Mesenchymal Stem Cell Transplantation ◽  
Novel Approach ◽  
Contemporary Status

AbstractSystemic sclerosis is a rare chronic autoimmune disease with extensive microvascular injury, damage of endothelial cells, activation of immune responses, and progression of tissue fibrosis in the skin and various internal organs. According to epidemiological data, women’s populations are more susceptible to systemic sclerosis than men. Until now, various therapeutic options are employed to manage the symptoms of the disease. Since stem cell-based treatments have developed as a novel approach to rescue from several autoimmune diseases, it seems that stem cells, especially mesenchymal stem cells as a powerful regenerative tool can also be advantageous for systemic sclerosis treatment via their remarkable properties including immunomodulatory and anti-fibrotic effects. Accordingly, we discuss the contemporary status and future perspectives of mesenchymal stem cell transplantation for systemic sclerosis.

Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al

2016 ◽  
Vol 68 (9) ◽  
pp. 2348-2348
Author(s):  
Paola Cipriani ◽  
Paola Di Benedetto ◽  
Vasiliki Liakouli ◽  
Roberto Giacomelli
Keyword(s):  
Stem Cell ◽  
Systemic Sclerosis ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mesenchymal Stem Cell Transplantation

scholarly journals Mesenchymal stem cell treatment for refractory pediatric rheumatic diseases: A single center case series

2020 ◽  
Author(s):  
Stephen Chee-Yung Wong ◽  
Leah C Medrano ◽  
Alice D Hoftman ◽  
Olcay Y Jones ◽  
Deborah K McCurdy
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Pediatric Rheumatology ◽  
Case Series ◽  
Infusion Therapy ◽  
Mesenchymal Stem Cell Transplantation ◽  
Mesenchymal Stem Cell Therapy

Abstract Background:Pediatric rheumatic disease treatment has seen a surge in innovative therapies including numerous biologic medications that show great potential. Yet, many children with advanced disease are not able to reach remission on available treatment. Mesenchymal stem cells have immunomodulatory properties, and transplantation of these stem cells have been used to successfully treat immunologic conditions like graft-versus-host disease. Mesenchymal stem cell research in adult lupus has been encouraging, but there is a lack of studies in pediatric rheumatology. This retrospective case series will highlight three children with refractory autoimmune disease who received mesenchymal stem cell therapy and review the potential benefits and risks of this emerging treatment modality.Case Presentation:Three children with established diagnoses of systemic lupus erythematosus, mixed connective tissue disease and juvenile idiopathic arthritis were under the care of pediatric rheumatology at a large, tertiary-care, teaching institution for many years. Multiple non-biologic and biologic disease-modifying anti-rheumatic drugs failed to significantly decrease disease activity, and as a result, the families chose to undergo mesenchymal stem cell therapy. After transplantation, all children improved and were able to taper off conventional immunosuppressive drugs. No serious adverse events occurred. Conclusion:The three cases presented in this study reflect comparable beneficial outcomes and minimal risks published in adult studies. Mesenchymal stem cell transplantation is a promising adjunctive treatment option that necessitates further research and development of standardized infusion therapy protocols.

scholarly journals Bone Regenerative Potential of Mesenchymal Stem Cells on a Micro- Structured Titanium Processed by Wire-Type Electric Discharge Machining

2010 ◽  
Vol 4 (1) ◽  
pp. 113-116 ◽  
Author(s):  
Yukimichi Tamaki ◽  
Yu Kataoka ◽  
In-Kee Jang ◽  
Takashi Miyazaki
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Electric Discharge ◽  
Functional Restoration ◽  
Titanium Implants ◽  
Electric Discharge Machining ◽  
Mesenchymal Stem Cell Transplantation ◽  
Scaffold Properties

A new strategy with bone tissue engineering by mesenchymal stem cell transplantation on titanium implant has been drawn attention. The surface scaffold properties of titanium surface play an important role in bone regenerative potential of cells. The surface topography and chemistry are postulated to be two major factors increasing the scaffold properties of titanium implants. This study aimed to evaluate the osteogenic gene expression of mesenchymal stem cells on titanium processed by wire-type electric discharge machining. Some amount of roughness and distinctive irregular features was observed on titanium processed by wire-type electric discharge machining. The thickness of suboxide layer was concomitantly grown during the processing. Since the thickness of oxide film and micro-topography allowed an improvement of mRNA expression of cells, titanium processed by wire-type electric discharge machining is a promising candidate for mesenchymal stem cell based functional restoration of implants.

scholarly journals MESENCHYMAL STEM CELL-BASED THERAPY FOR CHRONIC KIDNEY FAILURE RELATING LUPUS ERYTHEMATOSUS - A CASE REPORT

2021 ◽  
Vol 506 (1-2) ◽  
Author(s):  
Nguyen Duy Thang ◽  
Phan Thi Thuy Hoa ◽  
Phan Thi Dieu Ngan ◽  
Ngo Nhat Hoang ◽  
Che Thi Cam Ha
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Kidney Disease ◽  
Mesenchymal Stem Cell ◽  
Lupus Erythematosus ◽  
Cellular Interactions ◽  
Mesenchymal Stem Cell Transplantation ◽  
Cell Based Therapy

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which is characterized by systemic multiple-organ involvement, relapses with large amount of autoantibodies. Their pathophysiology is multifaceted, involves complex hormonal-immunological-cellular interactions, and leads to damage in multiple cell types, which is often resistant to conventional therapy. Thus, novel strategies are needed to repair the renal parenchyma and preserve kidney function. Mesenchymal stem cells (MSC) confer renal protection through paracrine/endocrine effects, and to some degree possibly by direct engraftment. The patient was diagnosed with chronic kidney disease by standard methods for more than fifteen years. The patient agreed to the treatment of autologous adipose mesenchymal stem cell transplantation. The adipose mesenchymal stem cells were harvested by surgery, isolated with our enzyme protocol. The patient received one injection with 2,6x106 cells/kg for a total of 43kg of body weight. The patient with SLE do not receive prompt treatment, he get irreversible organ damage. After seven months, the preexisting renal insufficiency gradually ameliorated, including the decrease of creatinine and blood urea as well as the increase of estimated glomerular filtration rate. Lupus symptoms also reduced, followed by the improvement of body movement and medication reduction.There was insufficient evidence of the clinical setting to show the efficiency of mesenchymal stem cells on the lupus nephritis relating to chronic kidney disease.  This clinical trial highlights the feasibility and safety of mesenchymal stem cell treatments in renal failure-associated- autoimmune diseases.

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

2010 ◽  
Vol 16 (4) ◽  
pp. 503-510 ◽  
Author(s):  
Mark S Freedman ◽  
Amit Bar-Or ◽  
Harold L Atkins ◽  
Dimitrios Karussis ◽  
Francesco Frassoni ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Central Nervous System ◽  
Nervous System ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mesenchymal Stem Cell Transplantation

Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based therapies may provide a new strategy for bolstering regeneration and repair through neuro-axonal protection or remyelination. Mesenchymal stem cells modulate pathological responses in experimental autoimmune encephalitis, alleviating disease, but also stimulate repair of the central nervous system through the release of soluble factors. Autologous and allogeneic mesenchymal stem cells have been safely administered to individuals with hemato-oncological diseases and in a limited number of patients with multiple sclerosis. It is therefore reasonable to move mesenchymal stem cells transplantation into properly controlled human studies to explore their potential as a treatment for multiple sclerosis. Since it is likely that the first such studies will probably involve only small numbers of patients in a few centers, we formed an international panel comprising multiple sclerosis neurology and stem cell experts, as well as immunologists. The aims were to derive a consensus on the utilization of mesenchymal stem cells for the treatment of multiple sclerosis, along with protocols for the culture of the cells and the treatment of patients. This article reviews the consensus derived from our group on the rationale for mesenchymal stem cell transplantation, the methodology for generating mesenchymal stem cells and the first treatment protocol for multiple sclerosis patients.

Sign in / Sign up

Export Citation Format

Share Document